Author:
Minet Emmanuel,Haswell Linsey E.,Corke Sarah,Banerjee Anisha,Baxter Andrew,Verrastro Ivan,De Abreu e Lima Francisco,Jaunky Tomasz,Santopietro Simone,Breheny Damien,Gaça Marianna D.
Abstract
AbstractMucus hypersecretion contributes to lung function impairment observed in COPD (chronic obstructive pulmonary disease), a tobacco smoking-related disease. A detailed mucus hypersecretion adverse outcome pathway (AOP) has been constructed from literature reviews, experimental and clinical data, mapping key events (KEs) across biological organisational hierarchy leading to an adverse outcome. AOPs can guide the development of biomarkers that are potentially predictive of diseases and support the assessment frameworks of nicotine products including electronic cigarettes. Here, we describe a method employing manual literature curation supported by a focused automated text mining approach to identify genes involved in 5 KEs contributing to decreased lung function observed in tobacco-related COPD. KE genesets were subsequently confirmed by unsupervised clustering against 3 different transcriptomic datasets including (1) in vitro acute cigarette smoke and e-cigarette aerosol exposure, (2) in vitro repeated incubation with IL-13, and (3) lung biopsies from COPD and healthy patients. The 5 KE genesets were demonstrated to be predictive of cigarette smoke exposure and mucus hypersecretion in vitro, and less conclusively predict the COPD status of lung biopsies. In conclusion, using a focused automated text mining and curation approach with experimental and clinical data supports the development of risk assessment strategies utilising AOPs.
Publisher
Springer Science and Business Media LLC
Reference45 articles.
1. Murphy, J. et al. Assessing modified risk tobacco and nicotine products: Description of the scientific framework and assessment of a closed modular electronic cigarette. Regul. Toxicol. Pharmacol. 90, 342–357 (2017).
2. ICH. S2 Guidance on genotoxicity testing and data interpretation for pharmaceuticals intended for human use, ICH harmonised tripartite guideline (S2(R1)). 2011 06 Sep 2019]; Available from: https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S2_R1/Step4/S2R1_Step4.pdf.
3. BeruBe, K., et al. In vitro models of inhalation toxicity and disease. The report of a FRAME workshop. Altern. Lab. Anim. 37(1), 89–141 (2009).
4. Breheny, D.O., Pant, K., Gaça, M. Comparative tumor promotion assessment of e-cigarette and cigarettes using the in vitro Bhas 42 cell transformation assay. Environ. Mol. Mutagen. 58(0893–6692), 190–198 (2017).
5. Taylor, M. et al. A comparative assessment of e-cigarette aerosols and cigarette smoke on in vitro endothelial cell migration. Toxicol. Lett. 277, 123–128 (2017).
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献